EpiHeart is young life science company dedicated to improve long term survival and quality of life of the patients having Cardiac Arterry Bypass Grafting (CABG). Based on intial pre-clinical and clincal results the epicardial transplantation of autologous cells during the CABG surgery reduces the scar tissue and fibrosis causing heart failures
EpiHeart is a spin-off company leverageing over 10 years of dedicated research conducted on three continents. Our home is Helsinki, Finland, where we have deep collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
Epiheart is open for collaboration. We foresee collaboration possibilites:
Feel free to request further information on our scince, clinical trial program and more.
Tel. +358 40 751 6763
Haartmaninkatu 8, 00290 Helsinki, Finland